Androgens and erythropoiesis.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000728:Androgens / Q000009:adverse effects / Q000494:pharmacology*; D000732:Androstanols / Q000627:therapeutic use; D000741:Anemia, Aplastic / Q000188:drug therapy; D001853:Bone Marrow / Q000502:physiology; D056486:Chemical and Drug Induced Liver Injury; D003365:Costs and Cost Analysis; D004305:Dose-Response Relationship, Drug; D004920:Erythropoiesis / Q000187:drug effects*; D005474:Fluoxymesterone / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007938:Leukemia; D008696:Methandrostenolone / Q000627:therapeutic use; D008777:Methyltestosterone / Q000627:therapeutic use; D009277:Nandrolone / Q000627:therapeutic use; D013197:Stanozolol / Q000627:therapeutic use; D013739:Testosterone / Q000627:therapeutic use; D013997:Time Factors
D000305:Adrenal Cortex Hormones; D000728:Androgens; D000732:Androstanols; D005938:Glucocorticoids; D013739:Testosterone; D013197:Stanozolol; D009277:Nandrolone; D005474:Fluoxymesterone; D008696:Methandrostenolone; D008777:Methyltestosterone